GSK Vaccines Institute for Global Health

The GSK Vaccines Institute for Global Health (GVGH) is a non-profit research institute based in Siena, Italy, dedicated to developing affordable vaccines for diseases that disproportionately affect people in developing countries. Originally founded by Novartis and later integrated into GSK, the institute bridges the gap between academic research and industrial vaccine development. GVGH utilizes its proprietary Generalized Modules for Membrane Antigens (GMMA) platform to create innovative vaccines against high-impact pathogens such as Salmonella and Shigella. By partnering with global health organizations and manufacturers in low- and middle-income countries, GVGH ensures that its life-saving technologies are accessible to the populations with the highest disease burden. Their pipeline includes advanced programs for typhoid fever, invasive non-typhoidal salmonella, and shigellosis.